Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
Rhea-AI Summary
Nexentis (NASDAQ:NXTS) reported that its subsidiary MitoCareX Bio has achieved its first drug discovery milestone since acquisition: an optimized hit molecule with substantially improved pharmaceutical properties versus the initial hit compound.
The molecule was generated using the proprietary MITOLINE® algorithm, which models mitochondrial SLC25 carrier proteins and supports progression toward a lead molecule and pre-clinical development for hard-to-treat cancers and inflammatory metabolic diseases.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- First drug discovery milestone achieved at MitoCareX since its acquisition by Nexentis
- Optimized hit molecule shows substantially improved pharmaceutical properties versus initial hit compound
- MITOLINE® algorithm enabled reliable 3D models of mitochondrial SLC25 carrier protein targets
- Program advancing toward a lead molecule and pre-clinical trials
- Improved metabolic stability and drug-like properties demonstrated as of March 31, 2026
- Targets hard-to-treat cancers and inflammatory metabolic diseases within large, growing markets
Negative
- None.
News Market Reaction – NXTS
On the day this news was published, NXTS gained 10.76%, reflecting a significant positive market reaction. Argus tracked a peak move of +31.9% during that session. Argus tracked a trough of -15.2% from its starting point during tracking. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $443K to the company's valuation, bringing the market cap to $4.56M at that time. Trading volume was very high at 4.8x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-05-13 | Drug discovery milestone | Positive | +1.7% | Announced optimized hit molecule with improved pharmaceutical properties at MitoCareX. |
| 2026-05-05 | IP / platform update | Positive | +1.5% | Received U.S. trademark registration for MITOLINE™ algorithm platform. |
| 2026-03-13 | Corporate repositioning | Positive | +0.0% | Launched new website highlighting AI-driven MITOLINE™ platform and RTB solar model. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent MITOLINE®/MitoCareX news has been positive and historically coincided with modestly positive price reactions.
Over recent months, Nexentis has highlighted progress around its MitoCareX subsidiary and MITOLINE® platform. On May 13, 2026, it reported an optimized hit molecule with improved pharmaceutical properties, and on May 5, 2026, it secured U.S. trademark registration for MITOLINE™. A March 13, 2026 website launch showcased its AI-driven biotech and RTB solar model. Today’s milestone update extends this same drug discovery and platform narrative.
Key Terms
mitochondrial carrier protein medical
slc25 medical
small molecule medical
oncology medical
cagr financial
pre-clinical trials regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.
This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that the Company's proprietary MITOLINE® algorithm platform can power a drug discovery and development progression in a target class that has historically been difficult to drug. MITOLINE® - the U.S. trademark-registered algorithm whose registration was announced by Nexentis in May 2026 enabled the identification of the program's initial hit molecule by generating reliable 3D structural models of a mitochondrial carrier protein in the SLC25 family, overcoming a central bottleneck in mitochondrial drug discovery: the near-total absence of experimentally solved 3D structures for this important protein class. The initial hit was identified by MITOLINE®-enabled virtual screenings and has now undergone systematic medicinal chemistry optimization, culminating in the generation of an optimized hit molecule that demonstrates clear improvements across key pharmaceutical parameters assessed as of March 31, 2026.
MitoCareX's program is advancing a novel small molecule drug candidate targeting a mitochondrial SLC25 carrier protein, developed to potentially address hard-to-treat cancers and inflammatory metabolic diseases. Oncology and inflammatory disease together represent one of the most dynamic and capital-intensive spaces in global pharma - with the cancer therapy market alone projected to grow from approximately
"Achieving our first drug discovery milestone since the acquisition of MitoCareX, is a testament to the power of the MITOLINE® platform and the quality of MitoCareX's drug discovery team," said David Palach, Chief Executive Officer of Nexentis Technologies. "MITOLINE® gave us the structural insight to identify a differentiated starting point for our medicinal chemistry program. The team has now built on that foundation by generating optimized molecules with demonstrated improvements in metabolic stability and drug-like properties - bringing us meaningfully closer to a lead molecule. We look forward to advancing to our next milestones and continuing to potentially build value for our shareholders."
MitoCareX is advancing towards pre-clinical trials and generating a lead molecule, building on the structural and medicinal chemistry foundation established through the MITOLINE® platform.
About Nexentis Technologies Inc.
Nexentis Technologies Inc. (NASDAQ: NXTS)
For additional details, please visit www.nexentistech.com
Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the progress of MitoCareX's drug discovery program, the expected growth of the cancer therapy market and advancing to its next milestones and continuing to potentially build value for its shareholders. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Nexentis Technologies’ and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Nexentis Technologies’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.
Investor Relations Contact:
Michal Efraty
michal@efraty.com
